Xenon Pharmaceuticals
XENE
58 hedge funds and large institutions have $110M invested in Xenon Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 23 increasing their positions, 6 reducing their positions, and 12 closing their positions.
283% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 6
0% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 12
1.22% less ownership
Funds ownership: 70.37% → 69.15% (-1.2%)
2% less funds holding
Funds holding: 59 → 58 (-1)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
53% less capital invested
Capital invested by funds: $234M → $110M (-$124M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$5.54M |
| 2 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$3.19M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.89M |
| 4 |
BlackRock
New York
|
+$2.52M |
| 5 |
JP Morgan Chase
New York
|
+$1.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$11.8M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$7.01M |
| 3 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$5.09M |
| 4 |
JG
Jefferies Group
New York
|
-$4.3M |
| 5 |
BC
Boxer Capital
San Diego,
California
|
-$3.96M |
XENE Hedge Fund Activity: Q4 2018 in Review
58 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q4 2018, worth a combined $110M — down 53% from $234M a quarter earlier.
Fund positioning in XENE was balanced in Q4 2018: 12 funds opened new positions, 12 closed out, 23 added to existing stakes and 6 trimmed.
The largest buyer was BVF Inc, adding an estimated $5.54M. The largest seller was Broadfin Capital, exiting entirely with an estimated $11.8M sold.
- 58 institutional investors held Xenon Pharmaceuticals (XENE) as of Q4 2018, down from 59 in Q3 2018.
- Funds reported $110M of Xenon Pharmaceuticals stock for Q4 2018, down 53% quarter-over-quarter.
- 12 funds opened new Xenon Pharmaceuticals positions in Q4 2018 and 12 closed out, a net change of 0 holders.
- The largest Xenon Pharmaceuticals buyer in Q4 2018 was BVF Inc, an estimated $5.54M added.
- The largest Xenon Pharmaceuticals seller in Q4 2018 was Broadfin Capital, an estimated $11.8M sold.
Based on aggregated 13F filings for Q4 2018.